RecruitingPHASE2, PHASE3NCT04061512

Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia

Studying Waldenström macroglobulinemia

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University College, London
Intervention
Dexamethasone, cyclophosphamide, rituximab(drug)
Enrollment
148 target
Eligibility
18 years · All sexes
Timeline
2020 – 2030

Study locations (25)

Collaborators

Janssen-Cilag Ltd.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04061512 on ClinicalTrials.gov

Other trials for Waldenström macroglobulinemia

Additional recruiting or active studies for the same condition.

See all trials for Waldenström macroglobulinemia →

← Back to all trials